NCT03405597

HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 97 (estimated)
• Sponsor: Mahidol University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

Chronic HBV infection is major problem in Asian countries. Years after chronic infection, in some cases serum HBsAg level declines to unmeasurable level. Some of patients develop anti-HBsAb but there is no standard treatment to accelerate HBsAg seroconversion. There is a study to determine efficacy and safety of HBV vaccine in who is Chronic HBV infection and lost their HBsAg without seroconversion to anti-HBsAb.

Conditions

• Chronic Hepatitis B, HBsAg, Hepatitis B Vaccine

Interventions

Type	Name	Description
DRUG	Commercial Hepatitis B vaccine	Commercial Hepatitis B vaccine (Engerix B) 20 microgram subcutaneous injection at month 0, 1, 6
OTHER	Standard Treatment	HBsAg, HBsAb test Ultrasound upper abdomen every 6 months

Timeline

• Start date: 2017-03-30
• Primary completion: 2018-02-28
• Completion: 2018-06-30
• First posted: 2018-01-23
• Last updated: 2018-01-23

Locations

1 site across 1 country: Thailand